Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Clinical trial NCT04803851 · UNKNOWN
Trial details
- NCT number
- NCT04803851
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-12
- Primary completion
- 2024-02-28
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.